EMA recommends suspension, recall of Zinbryta
The European Medicines Agency is now recommending the immediate suspension and recall of Biogen’s multiple sclerosis therapy Zinbryta, just days after announcing a safety review.
Read More
Tag: recall
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
